Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →. With Astellas Pharma Inc.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
599actual
Sites
313
Countries
Argentina, Australia, Belgium +24
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-12 | actual | When the study began enrolling |
| Primary completion | 2026-02-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-28 | estimated | The whole study's end, after follow-up |
| First posted | 2021-03-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prostate Cancer
Interventions
- Drug: talazoparib plus enzalutamide — also filed as Combination arm
- Drug: Placebo plus enzalutamide — also filed as Monotherapy arm
Primary outcome
what the primary-completion date above is the date OFradiological Progression-Free Survival
measured randomization up to 3 years
Publications
- PMID 42223064 — linked by the registry
- PMID 37882449 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed